ArticleBritish journal of haematology2018

A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results.

Andrew Spencer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.